INT67796

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 8.36
Pain Relevance 2.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (CTLA4) plasma membrane (CTLA4)
Anatomy Link Frequency
T cells 5
CD86 1
lymphocyte 1
immune system 1
CTLA4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Infliximab 19 100.00 Very High Very High Very High
Etanercept 11 100.00 Very High Very High Very High
Adalimumab 2 100.00 Very High Very High Very High
abatacept 133 99.84 Very High Very High Very High
rheumatoid arthritis 101 98.36 Very High Very High Very High
tolerance 26 96.08 Very High Very High Very High
spinal inflammation 1 95.44 Very High Very High Very High
Leflunomide 1 90.16 High High
Inflammation 24 89.68 High High
methotrexate 41 87.32 High High
Disease Link Frequency Relevance Heat
Melanoma 18 99.84 Very High Very High Very High
Necrosis 7 99.70 Very High Very High Very High
Cancer 447 99.52 Very High Very High Very High
Rheumatoid Arthritis 101 98.36 Very High Very High Very High
Disease 129 97.56 Very High Very High Very High
Skin Cancer 40 95.76 Very High Very High Very High
Low Back Pain 1 95.44 Very High Very High Very High
Glioma 100 90.56 High High
Autism 5 89.84 High High
INFLAMMATION 25 89.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CTLA4, like PDCD1, is a negative regulator of T-cell activation [32], and polymorphisms in this gene are associated with the onset of GD [33], [34].
Negative_regulation (regulator) of CTLA4 in T-cell associated with disease
1) Confidence 0.39 Published 2010 Journal PLoS Computational Biology Section Body Doc Link PMC2944780 Disease Relevance 1.39 Pain Relevance 0.12
In a skin transplant model, blockade of the CTLA-4 pathway abolishes immuno-regulation by CD4+CD25+ T-cells, suggesting that CTLA-4 is required for tolerance (Kingsley et al 2002).


Negative_regulation (blockade) of CTLA-4 in T-cells associated with tolerance
2) Confidence 0.37 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721321 Disease Relevance 0 Pain Relevance 0.05
Blockade of CTLA-4 by anti-CTLA-4 antibody enhances T cell responses and has elicited significant tumor regression in some cancer patients.
Negative_regulation (Blockade) of CTLA-4 in T cell associated with cancer
3) Confidence 0.36 Published 2008 Journal Cancer Immun. Section Abstract Doc Link 18503261 Disease Relevance 0.33 Pain Relevance 0.03
Thus, it was reasoned that a CTLA4-Ig protein with a higher avidity for CD86 could be developed.
Negative_regulation (developed) of CTLA4-Ig in CD86
4) Confidence 0.36 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998809 Disease Relevance 0.31 Pain Relevance 0.31
Therapeutic inhibition with CTLA4-Ig
Negative_regulation (inhibition) of CTLA4-Ig
5) Confidence 0.34 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582812 Disease Relevance 0.77 Pain Relevance 0.28
They suppressed IFN-gamma production and proliferation by CD4+ T cells in vitro in a cell contact-dependent manner, which could be blocked using a CTLA-4-specific mAb.
Negative_regulation (using) of CTLA-4-specific in T cells
6) Confidence 0.34 Published 2005 Journal Eur. J. Immunol. Section Abstract Doc Link 16180249 Disease Relevance 0.26 Pain Relevance 0.14
The blockade of CTLA-4 with specific, monoclonal antibodies (mAb) has been explored as a monotherapy or in combination with vaccine therapy in preclinical and clinical studies.
Negative_regulation (blockade) of CTLA-4
7) Confidence 0.30 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2840411 Disease Relevance 0.52 Pain Relevance 0
The early results using immunomodulator molecules have been encouraging (as an example CTLA4 blockade in melanoma patients [140]) and one trial in melanomas recently demonstrated the potential interest of combination of CTLA4 blockade with a DC vaccine [141].
Negative_regulation (blockade) of CTLA4 associated with melanoma
8) Confidence 0.19 Published 2010 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2952949 Disease Relevance 0.81 Pain Relevance 0
The early results using immunomodulator molecules have been encouraging (as an example CTLA4 blockade in melanoma patients [140]) and one trial in melanomas recently demonstrated the potential interest of combination of CTLA4 blockade with a DC vaccine [141].
Negative_regulation (blockade) of CTLA4 associated with melanoma
9) Confidence 0.16 Published 2010 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2952949 Disease Relevance 0.84 Pain Relevance 0.03
However, CTLA4 blockade is a mode of non-specific immune activation by abrogating a negative regulatory mechanism of the immune system.
Negative_regulation (blockade) of CTLA4 in immune system
10) Confidence 0.16 Published 2010 Journal J Transl Med Section Body Doc Link PMC2954849 Disease Relevance 0.82 Pain Relevance 0
They include tumour necrosis factor (TNF)- blocking agents such as infliximab, etanercept and adalimumab, the anti-CD 20 agent rituximab and CTLA-4 Ig abatacept.
Negative_regulation (blocking) of CTLA-4 associated with necrosis, infliximab, cancer, abatacept, adalimumab and etanercept
11) Confidence 0.07 Published 2007 Journal Ann. Acad. Med. Singap. Section Abstract Doc Link 17364080 Disease Relevance 0.68 Pain Relevance 0.50
In contrast inhibition of costimulatory molecules such as CTLA-4Ig was recently successful (Kremer et al 2005) in ameliorating disease pointing to activation of T cells as a target for therapy in RA.


Negative_regulation (inhibition) of CTLA-4Ig in T cells associated with rheumatoid arthritis and disease
12) Confidence 0.02 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661661 Disease Relevance 1.24 Pain Relevance 0.51
The behavioural improvement was accompanied by alterations in the distribution of the major lymphocyte subsets, with a significant increase of the T-helper-inducers (CD4+CD8-) and a significant reduction of the T-cytotoxic-suppressor (CD4-CD8+) resulting in a normalization of the CD4/CD8 ratio.
Negative_regulation (reduction) of T-cytotoxic-suppressor in lymphocyte
13) Confidence 0.01 Published 1996 Journal Ann. Ist. Super. Sanita Section Abstract Doc Link 9028057 Disease Relevance 0.38 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox